Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 209,922,980 papers from all fields of science
Search
Sign In
Create Free Account
ON012380
Known as:
ON 012380
, ON-012380
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Benzene Derivatives
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Proliferation centers in chronic lymphocytic leukemia: the niche where NF-κB activation takes place
B. Herreros
,
S. Rodríguez-Pinilla
,
+13 authors
M. Piris
Leukemia
2010
Corpus ID: 24187439
Proliferation centers in chronic lymphocytic leukemia: the niche where NF-κB activation takes place
2010
2010
ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells
J. Wu
,
F. Meng
,
+8 authors
N. Donato
Leukemia
2010
Corpus ID: 30831588
ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells
2009
2009
ON012380: A Non-ATP Competitive Inhibitor of BCR-ABL for the Therapy of Imatinib-Resistant CMLs
E. Reddy
2009
Corpus ID: 53868211
Abstract : Because it is now apparent that a significant proportion of patients chronically treated with imatinib develop…
Expand
Review
2006
Review
2006
Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
C. Walz
,
M. Sattler
Critical reviews in oncology/hematology
2006
Corpus ID: 1397174
Review
2006
Review
2006
The Second Generation of BCR-ABL Tyrosine Kinase Inhibitors
T. Tauchi
,
K. Ohyashiki
International journal of hematology
2006
Corpus ID: 8899183
Imatinib was developed as the first molecularly targeted therapy to specifically inhibit the BCR-ABL kinase in Philadelphia…
Expand
Review
2006
Review
2006
New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
S. Kimura
,
E. Ashihara
,
T. Maekawa
Current Pharmaceutical Biotechnology
2006
Corpus ID: 8064090
Imatinib mesylate, Abl tyrosine kinase inhibitor, has improved the treatment of Bcr-Abl-positive leukemia such as chronic myeloid…
Expand
Highly Cited
2005
Highly Cited
2005
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.
K. Gumireddy
,
S. Baker
,
+5 authors
E. Reddy
Proceedings of the National Academy of Sciences…
2005
Corpus ID: 25488644
Imatinib, which is an inhibitor of the BCR-ABL tyrosine kinase, has been a remarkable success for the treatment of Philadelphia…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE